How you can help exon skipping
Posted by: Christine McSherry on January 24, 2013
Join us at the FDA – Accelerated Approval for Eteplirsen
Posted by John Campbell on January 23, 2013
To all members of the Duchenne community:
For years, dozens of organizations have fought to find a treatment for Duchenne, a treatment that can save boys’ lives. Now, we’re closer than ever, but we need your help to make the final push.
On February 13th, with Change.org we will present more than 170,000 signatures in support of accelerated approval for Eteplirsen. This is the final push before the FDA makes its decision.
We need you there. We need to show the FDA that the Duchenne community wants and needs accelerated approval for Eteplirsen.
Sign up to join us in DC.
This is a watershed moment in the fight against Duchenne muscular dystrophy. By gaining accelerated approval for this treatment, we can save lives and pave the way for the development of additional treatments for Duchenne. Join us.Together we can change the lives of the thousands of families affected by Duchenne. Together we can make Duchenne history.
Bookmark the permalink | Tagged
pdufa fda patient-directed drug development patient perspectives duchenne muscular dystrophy harrison's fund duchenne allinace duchenne research alliance international invitation meeting duchenne muscular dystophy dmd treatment exon skipping sarepta eteplirsen dmd Permissible Risk Patient Perspective Duchenne Alliance PDUFA-V Fast Track Accelerated Approval Priority Review IND NDA Breakthrough therapy exon-skipping Duchenne muscular dystrophy collaboration rigorous review higher resolution. duchenne advocacy treatments pfizer children's hospital boston srpt $srpt jett foundation gower test biotech cambridge becker forbes healthcare rare disease new york times boston daily news prosensa moms morpholinos team community congress race to yes obama washington dc racetoyes washington white house petition fox business fox news stossel willis report government